3FL (3-Fucosyllactose) is a highly abundant, α1-3 fucosylated HMO in human milk. Some primary known benefits of 3FL include reducing infection by inhibiting the adhesion of pathogenic bacteria, regulating intestinal motility, and positively supporting gut health by selectively stimulating bifidobacteria.
GlyCare™ 3FL is presently undergoing development.
HMO help support immunity. Clinical studies have reported a relationship between HMO and immune outcomes in infants. HMO are reported to support an infant’s immune system. HMO may help reduce the risk of infection. HMO may help reduce the risk of certain infections in infants.
Clinical data suggest HMOs support intestinal health in infants. Preclinical and clinical data indicate that HMOs support the growth of beneficial bacteria/bifidobacteria. HMOs may help support the growth of beneficial bacteria/bifidobacteria which are believed to be important for immune and intestinal development and health.
Emerging data from pre-clinical models and breast milk studies suggest that HMOs may play a role reducing the incidence of certain allergic manifestations.